Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Minimal Residual Disease Detected by Liquid Biopsy
Peking University People's Hospital
45 participants
Jan 1, 2022
OBSERVATIONAL
Conditions
Summary
So far, MRD assessment by liquid biopsy (ctDNA) has not been used to predict postoperative treatment efficacy and recurrence risk of GIST patients because of special disease characteristics and technological limitations. Therefore, we conducted this prospective multi-center, single-arm observational study to collect 45 operable patients with locally advanced, suspected high-risk GIST. NGS genetic testing platform is used to detect tumour tissues and peripheral ctDNA will also be dectected. we try to explore the correlation between PFS/OS and MRD in high-risk GIST patients by analyzing the relationship between dynamic changes in ctDNA mutation spectrum and postoperative adjuvant therapy efficacy, and to evaluate MRD-based genomic characteristics to guide further treatment.
Eligibility
Inclusion Criteria6
- Patients aged between 18 and 80
- Patients suspected for high-risk GIST by preoperative imaging examinations or diagnosed with high-risk GIST by pathological biopsy, who have not received preoperative neoadjuvant treatment
- Patients must have not received any treatment including radiotherapy, chemotherapy or surgery
- The function of other organs including liver and kidneys is good enough so that the patients could tolerate targeted therapy and surgery
- Postoperative pathology conformed the diagnosis of high-risk GIST
- Patients and their families could understand the protocol of this study and voluntarily agree to participate in. Signed informed consents are required
Exclusion Criteria9
- Previous medical history of malignant tumors or synchronous other malignancies
- Emergent surgery because of bowel obstruction, perforation or bleeding
- Pregnant or lactant women
- Medical history of severe mental illness
- Patients with contraindication for targeted therapy and surgery
- Non-R0 resection
- Postoperative pathology conformed the diagnosis of non-high-risk GIST
- Patients with distant metastasis
- Other situations in which researchers consider that the patient is unsuitable for this study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05408897